Clinical Trial: Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07672496) titled 'Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection' on June 03.

Brief Summary: Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk. Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear. This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (>=18 years, SOFA>=2) at Fujian Medical University Union Hospital. Eligible patients are random...